ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study

Pfizer and Bristol Myers Squibb's anticoagulant superstar Eliquis has raced out to blockbuster sales in recent years and a big-time lead over its its warfarin alternative competitors. Looking to pad that lead, the partners are building a body of real-world evidence for their drug, and in one French study the results are mostly promising.